ライフサイエンスコーパス: antibody-drug conjugate

1 xture of protein-rich foods or in generating antibody-drug conjugates).

2 oxin, a chimeric monoclonal antibody, and an antibody drug conjugate.

3 ndent cell killing could be achieved with an antibody-drug conjugate.

4 ant prostate cancer with an STEAP1-targeting antibody-drug conjugate.

5 ingle-chemical entities will be the norm for antibody drug conjugates.

6 l isomer distribution within a population of antibody drug conjugates.

7 ntibodies are increasingly being adapted for antibody-drug conjugates.

8 therapy, including targeted approaches as in antibody-drug conjugates.

9 cations, including production of therapeutic antibody-drug conjugates.

10 hesis of new classes of stapled peptides and antibody-drug conjugates.

11 ion of some highly active new agents such as antibody-drug conjugates.

12 onary drug delivery, (vi) implants and (vii) antibody-drug conjugates.

13 tches, inhalers, drug reservoir implants and antibody-drug conjugates.

14 e toxic compounds used in current generation antibody-drug conjugates.

15 eukemia (AML) but has proven challenging for antibody-drug conjugates.

16 critical principles for efficacy, similar to antibody-drug conjugates.

17 account for the potency of disulfide-linked antibody-drug conjugates.

18 eckpoint inhibition, targeted therapies, and antibody-drug conjugates.

19 key to enabling online nRPLC-MS analysis of antibody-drug conjugates.

20 ncers (TNBCs), may be a potential target for antibody-drug conjugates.

21 The anti-EphA2 antibody-drug conjugate [1C1-maleimidocaproyl-MMAF (mcMM

22 To treat these patients, trastuzumab-based antibody-drug conjugates (ACDs) have been developed and

23 ed understanding of the mechanistic basis of antibody-drug conjugate activity will enable design of r

24 pyrrolobenzodiazepine (PBD)-based anti-CD19 antibody drug conjugate (ADC) being investigated for tre

25 cilitate the characterization of a subset of antibody drug conjugate (ADC) biotherapeutics, where the

26 platform to analyze an intact, lysine-linked antibody drug conjugate (ADC) in order to assess post tr

27 perty to selectively target melanoma with an antibody drug conjugate (ADC) specific to PMEL17, the pr

28 However, a novel auristatin E-based antibody drug conjugate (ADC), E-selectin antibody valin

29 Fifteen patients were treated with an antibody-drug conjugate (ADC) based on MSTP2109A; ADC tr

30 phase 2 study assessing the efficacy of the antibody-drug conjugate (ADC) brentuximab vedotin (BV) i

31 conjugated cytotoxic drugs, we generated an antibody-drug conjugate (ADC) by covalently linking the

32 ed the efficacy of sacituzumab govitecan, an antibody-drug conjugate (ADC) comprised of a humanized a

33 s spectrometric (HDX-MS) investigation of an antibody-drug conjugate (ADC) comprised of drug-linkers

34 Here we describe the generation of an antibody-drug conjugate (ADC) consisting of a humanized

35 A STING agonist antibody-drug conjugate (ADC) could overcome current lim

36 his study was to identify a novel target for antibody-drug conjugate (ADC) development in triple nega

37 We generated a novel antibody-drug conjugate (ADC) enfortumab vedotin compris

38 Conventional antibody-drug conjugate (ADC) manufacturing methods are

39 er and more effective characterization of an antibody-drug conjugate (ADC) product, compared to the s

40 An antibody-drug conjugate (ADC) provides the possibility o

41 We have developed a novel antibody-drug conjugate (ADC) that can selectively deliv

42 Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers

43 Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) that was approved recently

44 mitotic monomethyl auristatin E (MMAE)-based antibody-drug conjugate (ADC) therapy.

45 By analyzing the antibody-drug conjugate (ADC) using native desalting con

46 A chemically defined anti-CXCR4-auristatin antibody-drug conjugate (ADC) was synthesized that selec

47 Antibody-drug conjugate (ADC) which delivers cytotoxic d

48 ty of using tissue factor as a target for an antibody-drug conjugate (ADC), a panel of human tissue f

49 uctural characterization was performed on an antibody-drug conjugate (ADC), composed of an IgG1 monoc

50 r of IMGN529, a novel anti-CD37 maytansinoid antibody-drug conjugate (ADC), elegantly showing its act

51 preclinical efficacy of BAY 1187982, a novel antibody-drug conjugate (ADC).

52 al antibodies (mAbs) and derivatives such as antibody-drug conjugates (ADC) and bispecific antibodies

53 Antibody-drug conjugates (ADC) are an emerging drug clas

54 Antibody-drug conjugates (ADC) are designed to selective

55 However, many of the compounds used in such antibody-drug conjugates (ADC) are substrates for the mu

56 erization like bsAbs, antibody mixtures, and antibody-drug conjugates (ADC) as well as for biosimilar

57 Antibody-drug conjugates (ADC) comprise targeting antibo

58 Anti-CD70 antibody-drug conjugates (ADC) consisting of auristatin

59 Current antibody-drug conjugates (ADC) have made advances in eng

60 ally thought that the anticancer efficacy of antibody-drug conjugates (ADC) relies on their internali

61 Antibody-drug conjugates (ADC) target cytotoxic drugs to

62 Analysis of samples containing intact antibody-drug conjugates (ADC) using mass spectrometry p

63 Antibody-drug conjugates (ADC), potent cytotoxic drugs c

64 Complex biotherapeutic modalities, such as antibody-drug conjugates (ADC), present significant chal

65 ic conjugation technology used to synthesize antibody-drug conjugates (ADC).

66 ndow that are interesting for application in antibody-drug conjugates (ADC).

67 d embodied by the seven current FDA-approved antibody-drug conjugates (ADC).

68 ill target cells, for example in the form of antibody-drug conjugates (ADC).

69 ipient hematopoietic stem cells with a CD117-antibody-drug-conjugate (ADC).

70 Antibody drug conjugates (ADCs) are macromolecules compo

71 Antibody drug conjugates (ADCs) can undergo in vivo biot

72 (PK) assays are widely used in the field for antibody drug conjugates (ADCs) containing peptide linke

73 In vitro, these antibody drug conjugates (ADCs) exhibited significant cy

74 as powerful payloads for the development of antibody drug conjugates (ADCs) intended for personalize

75 ic agents to these nnAAs, yields homogeneous antibody drug conjugates (ADCs) that can be optimized fo

76 Antibody drug conjugates (ADCs) with PEGylated-maytansin

77 al antibodies (mAbs), bispecific antibodies, antibody drug conjugates (ADCs), and combination therapi

78 cant progress in the clinical application of antibody drug conjugates (ADCs), novel cleavage strategi

79 Antibody drug conjugates (ADCs), which harness the high

80 potencies that qualify them as payloads for antibody drug conjugates (ADCs), while a number of them

81 to antibodies resulting in the generation of antibody drug conjugates (ADCs).

82 Antibody-drug conjugates (ADCs) allow selective targetin

83 release of active drugs on tumor sites from antibody-drug conjugates (ADCs) and caged prodrugs.

84 e to RPLC-MS for peptide mapping analyses of antibody-drug conjugates (ADCs) and their parent antibod

85 With a number of antibody-drug conjugates (ADCs) approved for clinical us

86 Antibody-drug conjugates (ADCs) are a promising class of

87 ting toxicity of the small molecule payload, antibody-drug conjugates (ADCs) are administered at a mu

88 Antibody-drug conjugates (ADCs) are among the most promi

89 Antibody-drug conjugates (ADCs) are an important class o

90 Antibody-drug conjugates (ADCs) are an increasingly prev

91 Antibody-drug conjugates (ADCs) are designed to combine

92 Antibody-drug conjugates (ADCs) are designed to facilita

93 Interchain cysteine linked antibody-drug conjugates (ADCs) are emerging therapeutic

94 Antibody-drug conjugates (ADCs) are immunoconjugates com

95 For example, antibody-drug conjugates (ADCs) are increasingly common

96 While antibody-drug conjugates (ADCs) are now clinically estab

97 Antibody-Drug Conjugates (ADCs) are now established as a

98 Antibody-drug conjugates (ADCs) are promising agents for

99 Antibody-drug conjugates (ADCs) are promising therapies

100 Antibody-drug conjugates (ADCs) are protein therapeutics

101 Many antibody-drug conjugates (ADCs) are unstable in vivo bec

102 nker-drugs, anticipating the construction of antibody-drug conjugates (ADCs) as the ultimate goal of

103 with potential for use in the development of antibody-drug conjugates (ADCs) as well as being clinica

104 part of an effort to examine the utility of antibody-drug conjugates (ADCs) beyond oncology indicati

105 Antibody-drug conjugates (ADCs) combine the high specifi

106 Antibody-drug conjugates (ADCs) comprise antibodies cova

107 In this study, we investigated whether antibody-drug conjugates (ADCS) conjugated with pyrrolob

108 strategy for the preparation of homogeneous antibody-drug conjugates (ADCs) containing multiple payl

109 We improve the potency of antibody-drug conjugates (ADCs) containing the human epi

110 Antibody-Drug Conjugates (ADCs) developed as a targeted

111 m has been exploited with the development of antibody-drug conjugates (ADCs) for cancer chemotherapy.

112 postulate that GPC3 is a potential target of antibody-drug conjugates (ADCs) for treating liver cance

113 Antibody-drug conjugates (ADCs) harness the highly speci

114 The field of antibody-drug conjugates (ADCs) has gained significant m

115 Antibody-drug conjugates (ADCs) have a significant impac

116 Bispecific antibodies (bsAbs) and antibody-drug conjugates (ADCs) have already demonstrate

117 Antibody-drug conjugates (ADCs) have become a major clas

118 Therefore, antibody-drug conjugates (ADCs) have been developed to s

119 Antibody-drug conjugates (ADCs) have gained significant

120 though recent methods for the engineering of antibody-drug conjugates (ADCs) have gone some way to ad

121 cytic leukemia (CLL); however, CD37-directed antibody-drug conjugates (ADCs) have not been explored.

122 Antibody-drug conjugates (ADCs) have recently gained tra

123 ate of ~79 m(-1) s(-1) to produce functional antibody-drug conjugates (ADCs) in a one-step process.

124 d in most solid cancers, may be a target for antibody-drug conjugates (ADCs) in non-small-cell lung c

125 The recent success of antibody-drug conjugates (ADCs) in the treatment of canc

126 The in vitro potency of antibody-drug conjugates (ADCs) increases with the drug-

127 Targeting the tumor vasculature with antibody-drug conjugates (ADCs) is a promising anti-canc

128 Treatment of hematological malignancy with antibody-drug conjugates (ADCs) may cause liver injury.

129 Antibody-drug conjugates (ADCs) of defined structure hol

130 Antibody-drug conjugates (ADCs) offer increased efficacy

131 Antibody-drug conjugates (ADCs) polatuzumab vedotin (pol

132 Current strategies to produce homogeneous antibody-drug conjugates (ADCs) rely on mutations or ine

133 rogress has been made recently in developing antibody-drug conjugates (ADCs) that can selectively del

134 successfully used to engineer site-specific antibody-drug conjugates (ADCs) that exhibit cytotoxicit

135 Antibody-drug conjugates (ADCs) use antibodies to delive

136 Characterization of antibody-drug conjugates (ADCs) using mass spectrometry

137 The synthesis of antibody-drug conjugates (ADCs) using the interchain cys

138 Antibody-drug conjugates (ADCs) were prepared consisting

139 ched to tumor-targeting antibodies to create antibody-drug conjugates (ADCs), a number of which are n

140 Preparation of antibody-drug conjugates (ADCs), an emerging novel class

141 Antibody-drug conjugates (ADCs), an increasingly importa

142 himeric antigen receptor T cells (CAR-Ts) or antibody-drug conjugates (ADCs), are associated with sev

143 s of monoclonal antibodies (mAbs) as well as antibody-drug conjugates (ADCs), illustrating the possib

144 geting cytotoxic drugs to cancer cells using antibody-drug conjugates (ADCs), particularly those with

145 n synthesized via intermediate 19 for use in antibody-drug conjugates (ADCs).

146 of the innate immune system, and constructed antibody-drug conjugates (ADCs).

147 tio (DAR) and catabolite characterization of antibody-drug conjugates (ADCs).

148 h drugs to cysteine thiols for production of antibody-drug conjugates (ADCs).

149 tors that are clinically used as payloads in antibody-drug conjugates (ADCs).

150 nctional groups to enable the preparation of antibody-drug conjugates (ADCs).

151 rlin and taltobulin as cytotoxic payloads in antibody-drug conjugates (ADCs).

152 oading on a per-vehicle basis as compared to antibody-drug conjugates (ADCs).

153 DN18.2-targeting via a CD3-bispecific and an antibody drug conjugate and the characterization of thes

154 vel formulations of traditional chemotherapy-antibody drug conjugates and agents that target specific

155 logs were sufficient to support their use as antibody drug conjugates and potent in a breast cancer m

156 f two classes of complex biotherapeutics: an antibody-drug conjugate and a mAb-fusion biotherapeutic.

157 pproach using an LC-MS/MS experiment from an antibody-drug conjugate and its monoclonal antibody inte

158 tics, such as immunotoxins, immunoliposomes, antibody-drug conjugates and for targeted delivery of ge

159 potency of immunotherapeutic approaches with antibody-drug conjugates and immune checkpoint inhibitor

160 e natural products as potential payloads for antibody-drug conjugates and other delivery systems for

161 s study are highly desirable as payloads for antibody-drug conjugates and other drug delivery systems

162 ons ranging from probing protein function to antibody-drug conjugates and proteomics.

163 le for the generation of molecularly defined antibody-drug conjugates and radioimmunoconjugates.

164 h the clinical and industrial development of antibody-drug conjugates and small molecule-drug conjuga

165 ging, determining the therapeutic index with antibody drug conjugates, and dosing in radioimmunothera

166 n both the heavy and light chains of a model antibody-drug conjugate, and calculation of the overall

167 dition of payloads to proteins, synthesis of antibody-drug conjugates, and identification of hyperrea

168 n antibody (amatuximab), mesothelin-directed antibody drug conjugates (anetumab ravtansine, DMOT4039A

169 Our data support the use of an antibody-drug conjugate approach to selectively target a

170 and unusual story of GO, which was the first antibody-drug conjugate approved for human use by the FD

171 ber of fields, including therapeutics, where antibody-drug conjugates are an emerging area of biologi

172 However, we found that alpha-amanitin-based antibody-drug conjugates are highly effective therapeuti

173 Antibody-drug conjugates are monoclonal antibodies conju

174 Several promising antibody-drug conjugates are now in late-phase clinical

175 Antibody-drug conjugates are targeted anticancer agents

176 oclonal antibodies (mAbs), including several antibody-drug conjugates, are in advanced clinical devel

177 therapeutic target in CLL and for IgM-based antibody-drug conjugates as a new targeting platform.

178 The advent of antibody-drug conjugates as pharmaceuticals has fuelled

179 velopment of new anticancer drugs, including antibody-drug conjugates as potential targeted cancer th

180 fety of brentuximab vedotin, a CD30-directed antibody-drug conjugate, as frontline therapy in 27 HL p

181 A survey of several antibody drug conjugates based on the same IgG framework

182 This was achieved with an antibody drug conjugate between a novel, rationally desi

183 The antibody drug conjugate brentuximab vedotin is a new, hi

184 The antibody drug conjugate brentuximab vedotin is associate

185 by an enzyme-cleavable linker, producing the antibody-drug conjugate brentuximab vedotin (SGN-35).

186 The antibody-drug conjugate brentuximab vedotin delivers the

187 l outcomes of a pivotal phase 2 trial of the antibody-drug conjugate brentuximab vedotin in patients

188 calize the drug molecules in the therapeutic antibody-drug conjugate brentuximab vedotin, which displ

189 ess was achieved with the development of the antibody-drug-conjugate brentuximab vedotin.

190 he design strategies of the two FDA-approved antibody-drug conjugates (Brentuximab vedotin and Trastu

191 The CD30-specific antibody-drug conjugate, brentuximab vedotin, is approve

192 the selective cleavage of a tetrazine-linked antibody-drug conjugate by trans-cyclooctenes, affording

193 monomethyl auristatin E (MMAE) to create the antibody-drug conjugate cAC10-vcMMAE.

194 nd metabolism of the parent antibody and two antibody-drug conjugates, cAC10vc-MMAE and cAC10vc-MMAF,

195 Here we show that a single dose of a CD117-antibody-drug-conjugate (CD117-ADC) to saporin leads to

196 d provide a mechanistic basis for developing antibody-drug conjugates cleavable by intracellular prot

197 Trastuzumab emtansine (T-DM1), an antibody-drug conjugate composed of the cytotoxic agent

198 mab deruxtecan (also known as DS-8201) is an antibody-drug conjugate comprised of a humanised antibod

199 zumab duocarmazine is a novel HER2-targeting antibody-drug conjugate comprised of trastuzumab covalen

200 Trastuzumab emtansine (T-DM1), an antibody-drug conjugate comprising the cytotoxic agent D

201 e aimed to compare trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxic agent D

202 biomedicines, including half-life extension, antibody-drug conjugates, conjugate vaccines, bispecific

203 ty in rodent models relative to conventional antibody drug conjugates conjugated through either engin

204 y of mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate consisting of a humanized anti-f

205 Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazep

206 Polatuzumab vedotin is an antibody-drug conjugate containing an anti-CD79B monoclo

207 th auristatin as small molecule (MMAE) or as antibody-drug conjugate containing non-cleavable aurista

208 Affinity-attenuated bispecific EGFR x c-MET antibody-drug conjugates demonstrated high in vitro sele

209 plasia-related changes, and resurgence of an antibody-drug conjugate designed to target CD33.

210 Current antibody-drug conjugate designs that incorporate a disul

211 Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like prot

212 Tisotumab vedotin is a first-in-human antibody-drug conjugate directed against tissue factor,

213 Antibody drug conjugates enable the targeted delivery of

214 In the antibody-drug conjugate enfortumab vedotin, human anti-n

215 Antibody-drug conjugates enhance the antitumor effects o

216 e studies demonstrated that the antibody and antibody-drug conjugates entering target cells migrated

217 ies, bispecific antibodies, immunocytokines, antibody-drug conjugates, enzymes, polynucleotides, and

218 Design of effective antibody-drug conjugates for cancer therapy requires sel

219 ets, enabling the synthesis of site-specific antibody-drug conjugates for selective killing of HER2-p

220 litate future investigations directed toward antibody-drug conjugates for targeted cancer therapies a

221 tionale for developing optimally constructed antibody-drug conjugates for treating tumors that expres

222 CD33-directed antibody-drug conjugates (gemtuzumab ozogamicin) have be

223 The antibody-drug conjugate glembatumumab vedotin consists o

224 The antibody-drug conjugate glembatumumab vedotin links a fu

225 herapeutic antibodies and glycosite-specific antibody-drug conjugates (gsADCs) have generated great i

226 eckpoint inhibitors, targeted therapies, and antibody-drug conjugates have become options for certain

227 Antibody-drug conjugates have emerged as a powerful stra

228 Antibody-drug conjugates have produced remissions in acu

229 Antibody-drug conjugates hold considerable promise as an

230 Antibody-directed therapies in the form of antibody-drug conjugates, immune modulators, and antibod

231 r of these therapeutic approaches, including antibody-drug conjugates, immunotoxins, and targeted nuc

232 o a complete cycloaddition reaction with the antibody-drug conjugate in seconds vs hours for the pare

233 fficacy of brentuximab vedotin, an anti-CD30 antibody-drug conjugate, in relapsed/refractory CD30(+)

234 fety of brentuximab vedotin, a CD30-directed antibody-drug conjugate, in relapsed/refractory CD30(+)

235 ted by therapeutic anti-ERBB2 antibodies and antibody-drug conjugates, including trastuzumab, trastuz

236 Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epiderma

237 ted therapies, including small molecules and antibody-drug conjugates, is a viable alternative.

238 ders them insusceptible to Herceptin and its antibody-drug conjugate Kadcyla.

239 Targeted therapy with this CD30-directed antibody-drug conjugate may be an effective treatment fo

240 , and brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate, may have synergistic activity i

241 artic or serine protease inhibitors, blocked antibody-drug conjugate metabolism and the ensuing cytot

242 2 antibodies as model systems, site-specific antibody drug conjugates (NDCs) were produced, via oxime

243 clinical activity of anetumab ravtansine, an antibody-drug conjugate of anti-mesothelin antibody link

244 and in tumor xenograft models compared with antibody-drug conjugates of 11D10.

245 BBB-carrier arm in bispecific antibodies or antibody-drug conjugates offers an avenue to develop pha

246 es, biotherapeutics such as fusion proteins, antibody-drug conjugates, or bispecific antibodies may u

247 When applied to antibody-drug conjugates, our masked antibodies are pref

248 An analysis of Antibody-Drug Conjugate Payload manufacturing has reveal

249 The resulting chemically defined antibody-drug conjugates represent the first example in

250 Such molecules, termed immunotoxins and antibody-drug conjugates, respectively, represent a seco

251 rived xenografts, treatment with an anti-5T4 antibody-drug conjugate resulted in complete and sustain

252 The antibody-drug conjugate's mean half-life was 16.5 hours

253 the rapid rise of therapeutic antibodies and antibody-drug conjugates, significant investments have b

254 ), radioimmunoconjugates (radionuclide), and antibody drug conjugates (small-molecule drug).

255 their target tumours using platforms such as antibody-drug conjugates, small-molecule drug conjugates

256 possible to separate antibody fragments and antibody-drug conjugate species in less than 30 s.

257 4% sequence coverage was obtained for 25 kDa antibody drug conjugate subunits in online LC-MS experim

258 Unlike degradations associated with antibody drug conjugates, such biotransformations of tet

259 a second anti-HER2 agent, and trials of the antibody-drug conjugate T-DM1 (trastuzumab-emtansine) ha

260 well as adjuvant therapy with the anti-HER2 antibody-drug conjugate T-DM1, have all been approved fo

261 of a HER2 S310F-mutant PDX suggests that an antibody drug conjugate targeting HER2 would have superi

262 osing schedules of labetuzumab govitecan, an antibody-drug conjugate targeting carcinoembryonic antig

263 ety, and preliminary efficacy of SAR3419, an antibody-drug conjugate targeting CD19, in a first-in-ma

264 Brentuximab vedotin (BV) is an antibody-drug conjugate targeting CD30.

265 demonstrate the therapeutic potential of an antibody-drug conjugate targeting GPC2.

266 Polatuzumab vedotin, an antibody-drug conjugate targeting the CD79b component of

267 Antibodies and antibody-drug conjugates targeting the cell surface prot

268 Sacituzumab govitecan, an antibody-drug conjugate, targets Trop-2 for the selectiv

269 nalytical approach for ADCs, such as THIOMAB antibody-drug conjugates (TDCs), where the linker drugs

270 Trastuzumab emtansine (T-DM1) is an antibody drug conjugate that optimizes delivery of chemo

271 Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monocl

272 Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that combines the antitumor prop

273 These findings describe a glycan-specific antibody-drug conjugate that establishes polySia as a vi

274 s method can effectively create a homogenous antibody-drug conjugate that features a precise drug-to-

275 Finally, we develop a GPC2-directed antibody-drug conjugate that is potently cytotoxic to GP

276 Enfortumab vedotin is an antibody-drug conjugate that targets Nectin-4, which is

277 Trastuzumab-DM1 (T-DM1) is an antibody-drug conjugate that uses trastuzumab to specifi

278 Using the principle of antibody-drug conjugates that deliver highly potent cyto

279 protease-cleavable and reductively cleavable antibody-drug conjugates that were effective and stable

280 Antibody-drug conjugate therapy entails targeted killing

281 GSCs and that CD276 can be targeted with an antibody-drug conjugate to eliminate self-renewing cells

282 ives to the maleimides that are used in most antibody-drug conjugates to link Cys of mAbs with cytoto

283 inical benefit associated with antibodies or antibody-drug conjugates to STEAP1.

284 to the noncovalent interactions holding the antibody-drug conjugates together.

285 The antibody-drug conjugate trastuzumab emtansine (T-DM1) co

286 The antibody-drug conjugate trastuzumab emtansine is indicat

287 The antibody-drug conjugate trastuzumab-DM1 (T-DM1) combines

288 n inhibitor), antiestrogen therapies, and an antibody-drug conjugate (trastuzumab-DM1).

289 ief history of the emergence of the field of antibody-drug conjugates triggered more than a century a

290 ized and afucosylated antagonistic anti-BCMA antibody-drug conjugate via a noncleavable linker.

291 tial of ALPPL2 targeting, an ALPPL2-targeted antibody-drug conjugate was developed and demonstrated p

292 ety of brentuximab vedotin, a CD30 targeting antibody-drug conjugate, was evaluated in MF and SS.

293 roach to retaining the antitumor efficacy of antibody-drug conjugates, while minimizing their systemi

294 commercially relevant yields and can lead to antibody drug conjugates with improved properties relati

295 ruxtecan (DS-8201a) is a novel HER2-targeted antibody-drug conjugate with a humanised anti-HER2 antib

296 ruxtecan (DS-8201a) is a novel HER2-targeted antibody-drug conjugate with a humanised anti-HER2 antib

297 method was useful for building a homogeneous antibody-drug conjugate with a precise drug-to-antibody

298 SC16LD6.5) is a first-in-class DLL3-targeted antibody-drug conjugate with encouraging initial safety

299 Brentuximab vedotin is an anti-CD30 antibody-drug conjugate with proven efficacy in patients

300 n improve the intratumoral distribution of a antibody-drug conjugate, with implications for improving